I was at a cancer presentation and a doctor from Sloan-Kettering mentioned this as a very promising drug, I think he was referring to prostate cancer so it has more indications.
This shows you that if Roche wasn't involved and a smaller company was in control of the drug, they would have gone into phase 2 with the wrong dose and it would have been a failed drug.
Market Data 
Markets 
AI
